# A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

> **NCT02954406** · PHASE1 · TERMINATED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 43 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **DRUG:** TAK-659
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Lenalidomide
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02954406
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-03-05
- **Primary completion:** 2020-07-27
- **Final completion:** 2020-07-27
- **Target enrollment:** 43 (ACTUAL)
- **Why stopped:** Business decision, insufficient enrollment, no safety or efficacy concerns.
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02954406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02954406, "A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02954406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*